Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease
| dc.contributor.author | Bergamaschi, Laura | |
| dc.contributor.author | Mescia, Federica | |
| dc.contributor.author | Turner, Lorinda | |
| dc.contributor.author | Hanson, Aimee L. | |
| dc.contributor.author | Kotagiri, Prasanti | |
| dc.contributor.author | Dunmore, Benjamin J. | |
| dc.contributor.author | Ruffieux, Hélène | |
| dc.contributor.author | Sa, Aloka De | |
| dc.contributor.author | Huhn, Oisín | |
| dc.contributor.author | Morgan, Michael D. | |
| dc.contributor.author | Gerber, Pehuén Pereyra | |
| dc.contributor.author | Wills, Mark R. | |
| dc.contributor.author | Baker, Stephen | |
| dc.contributor.author | Calero-Nieto, Fernando J. | |
| dc.contributor.author | Doffinger, Rainer | |
| dc.contributor.author | Dougan, Gordon | |
| dc.contributor.author | Elmer, Anne | |
| dc.contributor.author | Goodfellow, Ian G. | |
| dc.contributor.author | Gupta, Ravindra K. | |
| dc.contributor.author | Hosmillo, Myra | |
| dc.contributor.author | Hunter, Kelvin | |
| dc.contributor.author | Kingston, Nathalie | |
| dc.contributor.author | Lehner, Paul J. | |
| dc.contributor.author | Matheson, Nicholas J. | |
| dc.contributor.author | Nicholson, Jeremy K. | |
| dc.contributor.author | Petrunkina, Anna M. | |
| dc.contributor.author | Richardson, Sylvia | |
| dc.contributor.author | Saunders, Caroline | |
| dc.contributor.author | Thaventhiran, James E.D. | |
| dc.contributor.author | Toonen, Erik J.M. | |
| dc.contributor.author | Weekes, Michael P. | |
| dc.contributor.author | Göttgens, Berthold | |
| dc.contributor.author | Toshner, Mark | |
| dc.contributor.author | Hess, Christoph | |
| dc.contributor.author | Bradley, John R. | |
| dc.contributor.author | Lyons, Paul A. | |
| dc.contributor.author | Smith, Kenneth G.C. | |
| dc.contributor.author | Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) Covid BioResource Collaboration | |
| dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.date.accessioned | 2023-03-09T17:43:01Z | |
| dc.date.available | 2023-03-09T17:43:01Z | |
| dc.date.issued | 2021-06-08 | |
| dc.description | Acknowledgements We thank all the patients and health care workers who consented to take part in this study. We are grateful to CVC Capital Partners, the Evelyn Trust (20/75), Addenbrooke's Charitable Trust, Cambridge University Hospitals (12/20A), the NIHR Cambridge Biomedical Research Centre, and the UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) for their financial support. Further support: K.G.C.S.: Wellcome Investigator Award (200871/Z/16/Z); M.P.W.: Wellcome Senior Clinical Research Fellowship (108070/Z/15/Z); C.H.: Wellcome COVID-19 Rapid Response DCF and the Fondation Botnar; N.M.: MRC (CSF MR/P008801/1), NHSBT (WPA15-02), and Addenbrooke's Charitable Trust, (grant ref. to 900239 NJM); I.G.G.: Wellcome Senior Fellowship and Wellcome grant (Ref: 207498/Z/17/Z); P.J.L.: Wellcome Trust Principal Research Fellowship (084957/Z/08/Z) and MRC (MR/V011561/1); J.K.N.: The Spinnaker Healthcare Research Trust and the McCusker Foundation as part of Australian National Phenome Centre. P.K. is the recipient of a Jacquot Research Entry Scholarship of the Royal Australasian College of Physicians Foundation. We would like to thank the NIHR Cambridge Clinical Research Facility outreach team for enrollment of patients; the NIHR Cambridge Biomedical Research Centre Cell Phenotyping Hub and the CRUK Cambridge Institute flow cytometry core facility for flow and mass cytometry; and the Cambridge NIHR BRC Stratified Medicine Core Laboratory NGS Hub (supported by an MRC Clinical Infrastructure Award) for RNA sequencing. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 28 | |
| dc.format.extent | 4408947 | |
| dc.identifier | 221553977 | |
| dc.identifier | e615dd19-dc0d-4c4e-b14b-59034945f403 | |
| dc.identifier | 85107023094 | |
| dc.identifier.citation | Bergamaschi, L, Mescia, F, Turner, L, Hanson, A L, Kotagiri, P, Dunmore, B J, Ruffieux, H, Sa, A D, Huhn, O, Morgan, M D, Gerber, P P, Wills, M R, Baker, S, Calero-Nieto, F J, Doffinger, R, Dougan, G, Elmer, A, Goodfellow, I G, Gupta, R K, Hosmillo, M, Hunter, K, Kingston, N, Lehner, P J, Matheson, N J, Nicholson, J K, Petrunkina, A M, Richardson, S, Saunders, C, Thaventhiran, J E D, Toonen, E J M, Weekes, M P, Göttgens, B, Toshner, M, Hess, C, Bradley, J R, Lyons, P A, Smith, K G C & Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) Covid BioResource Collaboration 2021, 'Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease', Immunity, vol. 54, no. 6, pp. 1257-1275.e8. https://doi.org/10.1016/j.immuni.2021.05.010 | en |
| dc.identifier.doi | 10.1016/j.immuni.2021.05.010 | |
| dc.identifier.iss | 6 | en |
| dc.identifier.issn | 1074-7613 | |
| dc.identifier.other | ORCID: /0000-0003-0757-0711/work/94584961 | |
| dc.identifier.uri | https://hdl.handle.net/2164/20265 | |
| dc.identifier.url | https://doi.org/10.1016/j.immuni.2021.05.010 | en |
| dc.identifier.url | https://europepmc.org/article/PMC/PMC8125900 | en |
| dc.identifier.vol | 54 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Immunity | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | SARS-CoV-2 | en |
| dc.subject | COVID-19 | en |
| dc.subject | bystander CD8+ T cell | en |
| dc.subject | recovery | en |
| dc.subject | immune pathology | en |
| dc.subject | systemic inflammation | en |
| dc.subject | complement | en |
| dc.subject | TNF-α | en |
| dc.subject | interferon | en |
| dc.subject | R Medicine | en |
| dc.subject | QR180 Immunology | en |
| dc.subject | Immunology and Allergy | en |
| dc.subject | Cell Biology | en |
| dc.subject | Infectious Diseases | en |
| dc.subject | Biochemistry | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | UK Research and Innovation (UKRI) | en |
| dc.subject | Wellcome Trust | en |
| dc.subject | 200871/Z/16/Z | en |
| dc.subject | 108070/Z/15/Z | en |
| dc.subject | 207498/Z/17/Z | en |
| dc.subject | 084957/Z/08/Z | en |
| dc.subject | Medical Research Council (MRC) | en |
| dc.subject | CSF MR/P008801/1 | en |
| dc.subject | MR/V011561/1 | en |
| dc.subject | Other | en |
| dc.subject | WPA15-02 | en |
| dc.subject | 900239 | en |
| dc.subject | Supplementary Data | en |
| dc.subject | https://www.covid19cellatlas.org/patient/citiid/ | en |
| dc.subject | EGAS00001005332 | en |
| dc.subject | FR-FCM-Z3XQ | en |
| dc.subject | FR-FCM-Z3SR | en |
| dc.subject | FR-FCM-Z3ST | en |
| dc.subject | FR-FCM-Z3SS | en |
| dc.subject | E-MTAB-10026 | en |
| dc.subject.lcc | R | en |
| dc.subject.lcc | QR180 | en |
| dc.title | Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Bergamaschi_etal_I_Longitudinal_Analysis_Reveals_VOR.pdf
- Size:
- 4.2 MB
- Format:
- Adobe Portable Document Format
